Browse our 650+ Publications
Latest Publications
Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma
Suvannasankha A, et al.
Cancer
August 2024
Authors and Affiliates
Attaya Suvannasankha MD1 | Nizar Bahlis MD2 | Suzanne Trudel MSc, MD3 |
Katja Weisel MD4 | Christian Koenecke MD5 | Albert Oriol MD, PhD6 |
Peter M. Voorhees MD7 | Aranzazu A. Alonso MD8 | Natalie S. Callander MD9 |
María‐Victoria Mateos MD, PhD10 | Nishitha Reddy MD11 | Shawn Hakim PhD12 |
John LaMacchia MD, PhD13 | Nashita Patel MSc, PhD14 | Danaé Williams MSc12 |
Roxanne C. Jewell PhD15 | Xiangdong Zhou PhD12 | Ira Gupta MD16 |
Joanna Opalinska MD12 | Ajay K. Nooka MD, MPH, FACP17
1
Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, Indiana, USA
2
Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada
3
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
4
University Medical Center Hamburg‐Eppendorf, Hamburg, Germany
5
Hannover Medical School, Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany
6
Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain
7
Levine Cancer Institute, Atrium Health/Wake Forest University School of Medicine, Charlotte, North Carolina, USA
8
Hospital Universitario Quirónsalud Madrid, Madrid, Spain
9
Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA
10Instituto de Investigación Biomédica de Salamanca and Centro de Investigación del Cáncer, Hospital Universitario de Salamanca, Salamanca, Spain
11Merck & Co., Inc, Rahway, New Jersey, USA
12GlaxoSmithKline, Upper Providence, Pennsylvania, USA
13GlaxoSmithKline, Waltham, Massachusetts, USA
14GlaxoSmithKline, Stevenage, UK
15GlaxoSmithKline, Durham, North Carolina, USA
16GlaxoSmithKline, Philadelphia, Pennsylvania, USA
17Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia, USA
Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation
Schneider-Hohendorf, et al.
Brain
July 2024
Authors and Affiliates
Tilman Schneider-Hohendorf, Christian Wünsch, Simon Falk, Catarina Raposo, Florian Rubelt, Hamid Mirebrahim, Hosseinali Asgharian, Ulrich Schlecht, Daniel Mattox, Wenyu Zhou, Eva Dawin, Marc Pawlitzki, Sarah Lauks, Sven Jarius, Brigitte Wildemann, Joachim Havla, Tania Kümpfel, Miriam-Carolina Schrot, Marius Ringelstein, Markus Kraemer, Carolin Schwake, Thomas Schmitter, Ilya Ayzenberg, Katinka Fischer, Sven G. Meuth, Orhan Aktas, Martin W. Hümmert, Julian R. Kretschmer, Corinna Trebst, Ilka Kleffner, Jennifer Massey, Paolo A. Muraro, Haiyin Chen-Harris, Catharina C. Gross, Luisa Klotz, Heinz Wiendl and Nicholas Schwab
Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN
Chari A, et al.
Blood Cancer Journal
July 2024
Authors and Affiliates
Ajai Chari 1,22✉, Jonathan L. Kaufman 2, Jacob Laubach 3, Douglas W. Sborov4, Brandi Reeves 5, Cesar Rodriguez1,
Rebecca Silbermann6, Luciano J. Costa 7, Larry D. Anderson Jr 8, Nitya Nathwani9, Nina Shah10, Naresh Bumma11,
Sarah A. Holstein 12, Caitlin Costello13, Andrzej Jakubowiak 14, Tanya M. Wildes12, Robert Z. Orlowski 15, Kenneth H. Shain16,
Andrew J. Cowan17, Huiling Pei18, Annelore Cortoos19, Sharmila Patel19, Thomas S. Lin19, Peter M. Voorhees 20✉,
Saad Z. Usmani 21✉ and Paul G. Richardson
1Icahn School of Medicine at Mount Sinai, New York, NY, USA. 2Winship Cancer Institute, Emory University, Atlanta, GA, USA. 3Dana-Farber Cancer Institute, Harvard Medical
School, Boston, MA, USA. 4Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA. 5University of North Carolina–Department of
Medicine–Chapel Hill, Chapel Hill, NC, USA. 6Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA. 7University of Alabama at Birmingham, Birmingham,
AL, USA. 8Myeloma, Waldenstrӧm’s and Amyloidosis Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX, USA. 9Judy and Bernard
Briskin Center for Multiple Myeloma Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA. 10University of California San Francisco, San Francisco, CA, USA.
11Division of Hematology, The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA. 12Division of Oncology and Hematology, Department of Internal
Medicine, University of Nebraska Medical Center, Omaha, NE, USA. 13Moores Cancer Center, University of California San Diego, La Jolla, CA, USA. 14University of Chicago Medical
Center, Chicago, IL, USA. 15Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. 16Department of Malignant Hematology,
H. Lee Moffitt Cancer Center, Tampa, FL, USA. 17Clinical Research Division, Fred Hutch Cancer Center, Seattle, WA, USA. 18Janssen Research & Development, LLC, Titusville, NJ,
USA. 19Janssen Scientific Affairs, LLC, Horsham, PA, USA. 20Levine Cancer Institute, Atrium Health Wake Forest University School of Medicine, Charlotte, NC, USA. 21Memorial Sloan
Kettering Cancer Center, New York, NY, USA. 22Affiliation at the time of study conduct.
A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia
Srinagesh H, et al.
Blood
July 2024
Authors and Affiliates
Hrishikesh Srinagesh1
, Clayton Jackson2
, Parveen Shiraz3
, Nikeshan Jeyakumar1
, Mark
Hamilton1
, Emily Egeler4
, Sharon Mavroukakis4
, Adam Kuo4
, Juancarlos Cancilla4
, Bita
Sahaf4
, Neha Agarwal3
, Alyssa Kanegai3
, Anne Marijn Kramer3,4
, Sally Arai3
, Sushma
Bharadwaj3
, Saurabh Dahiya3
, Hitomi Hosoya3
, Laura Johnston3
, Vanessa Kennedy3
,
Michaela Liedtke1
, Robert Lowsky3
, Lekha Mikkilineni3
, Robert Negrin3
, Andrew
Rezvani3
, Surbhi Sidana3
, Judith Shizuru3
, Melody Smith3
, Wen-Kai Weng3
, Steven
Feldman4
, Matthew J. Frank3,4
, Zachary Lee5
, Mary Tagliaferri5
, A. Mario Marcondes5
,
David Miklos3,4
, Crystal Mackall4
, Lori Muffly3,4
Division of
Hematology/Oncology, UT Southwestern, Dallas, TX; 3
Division of Blood and Marrow
Transplantation and Cellular Therapy, Stanford University, Stanford CA; 4
Center for
Cancer Cell Therapy, Stanford University, Stanford, CA;
5
Nektar Therapeutics, San
Francisco, CA
Molecular disease monitoring in patients with relapsed/refractory B-cell lymphoma receiving anti-CD19 CAR T-cell therapy
Colton M, et al.
Clinical Lymphoma Myeloma & Leukemia
June 2024
Authors and Affiliates
Colton, Meryl MD MSc1; Purev, Enkhtsetseg MD1; Haverkos, Bradley MD MPH1; Bair, Steven
MD1; Jasem, Jagar MD MPH1; Allison Jacob MS2; Kamdar, Manali MD1
1. Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation,
University of Colorado Cancer Center, Aurora, CO
2. Adaptive Biotechnologies, Seattle WA
Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma
Melani C, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
C. Melani, R. Lakhotia, S. Pittaluga, J.D. Phelan, D.W. Huang, G. Wright, J. Simard, J. Muppidi, C.J. Thomas,
M. Ceribelli, F.A. Tosto, Y. Yang, W. Xu, T. Davies‑Hill, S.D. Pack, C.J. Peer, O. Arisa, E. Mena, L. Lindenberg,
E. Bergvall, C.A. Portell, R.J. Farah, S.T. Lee, A. Pradhan, C. Morrison, A. Tadese, A.M. Juanitez, C. Lu, A. Jacob,
H. Simmons, W.D. Figg, S.M. Steinberg, E.S. Jaffe, M. Roschewski, L.M. Staudt, and W.H. Wilson
Lymphoid Malignancies Branch (C. Melani, R.L., J.D.P., D.W.H., J.S., J.M., Y.Y., W.X., A.P., C. Morrison, A.T., A.M.J., M.R., L.M.S., W.H.W.), the Clinical Pharmacology Program (C.J.P., O.A., W.D.F.), the Molecular Imaging Branch (E.M., L.L., E.B.), and the Biostatistics and Data Management Section (S.M.S.), Center for Cancer Research, the Laboratory of Pathology, Clinical Center (S.P., T.D.-H., S.D.P., E.S.J.), and the Biometric Research Program, Division of Cancer Treatment and Diagnosis (G.W.), National Cancer Institute, the Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences (C.J.T., M.C., F.A.T.), and the Clinical Center Pharmacy Department (C.L.), National Institutes of Health, Bethesda, and Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore (S.T.L.) — all in Maryland; the Division of Hematology and Oncology, University of Virginia, Charlottesville (C.A.P.); Mario Lemieux Center for Blood Cancers, University of Pittsburgh School of Medicine, Pittsburgh (R.J.F.); and Adaptive Biotechnologies, Seattle (A.J., H.S.)
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
Bumma N, et al.
Journal of Clinical Oncology
June 2024
Authors and Affiliates
Naresh Bumma, MD1; Joshua Richter, MD2 ; Sundar Jagannath, MD2 ; Hans C. Lee, MD3 ; James E. Hoffman, MD4;
Attaya Suvannasankha, MD5 ; Jeffrey A. Zonder, MD6 ; Mansi R. Shah, MD7 ; Suzanne Lentzsch, MD, PhD8 ; Rachid Baz, MD9 ;
Joseph J. Maly, MD10; Swathi Namburi, MD11; Matthew J. Pianko, MD12 ; Jing Christine Ye, MD, MS12; Ka Lung Wu, MD, PhD13 ;
Rebecca Silbermann, MD14 ; Chang-Ki Min, MD15; Marie-Christiane Vekemans, MD16; Markus Munder, MD17 ; Ja Min Byun, MD18 ;
Joaqu´ın Mart´ınez-Lopez, MD19 ; Kaniel Cassady, PhD20 ; Michelle DeVeaux, PhD20; Dhruti Chokshi, BS20; Anita Boyapati, PhD20;
Anasuya Hazra, PhD20; George D. Yancopoulos, MD, PhD20; L. Andres Sirulnik, MD, PhD20; Karen Rodriguez Lorenc, MD20; Glenn S. Kroog, MD20 ;
Yariv Houvras, MD, PhD20; and Madhav V. Dhodapkar, MD21
1The Ohio State University Comprehensive Cancer Center, Columbus,
OH
2Icahn School of Medicine at Mount Sinai, New York, NY
3The University of Texas MD Anderson Cancer Centre, Houston, TX
4University of Miami Health System, Miami, FL
5Indiana University Simon Cancer Center and Roudebush VAMC,
Indianapolis, IN
6Karmanos Cancer Institute, Detroit, MI
7Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
8Columbia University Medical Center, New York, NY
9Department of Malignant Hematology, H. Lee Moffitt Cancer Center,
Tampa, FL
10Norton Cancer Institute, Louisville, KY
11Swedish Cancer Institute, Seattle, WA
12Rogel Cancer Center, University of Michigan Medical School, Ann
Arbor, MI
13Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium
14Knight Cancer Institute, Oregon Health & Science University, Portland,
OR
15Department of Hematology, College of Medicine, Catholic Hematology
Hospital and Leukemia Research Institute, Seoul St Mary’s Hospital,
The Catholic University of Korea, Seoul, South Korea
16Department of Hematology, Cliniques Universitaires Saint-Luc,
Universit´e Catholique de Louvain (UCLouvain), Brussels, Belgium
17Department of Internal Medicine III, University Medical Center Mainz,
Mainz, Germany
18Department of Internal Medicine, Seoul National University College of
Medicine, Seoul National University Hospital, Seoul, Korea
19Hospital 12 de Octubre, i112, School of Medicine Universidad
Complutense, CNIO, Madrid, Spain
20Regeneron Pharmaceuticals, Inc, Tarrytown, NY
21Emory University School of Medicine, Atlanta, GA
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1):a phase 2 cohort of a single-arm, multicentre study
Linton K, et al.
Lancet Haematology
June 2024
Bortezomib, thalidomide, and dexamethasone with or without daratumumab and followed by daratumumab maintenance or observation in transplant-eligible newly diagnosed multiple myeloma: long-term follow-up of the CASSIOPEIA randomised controlled phase 3 trial
Moreau P, et al
Lancet Oncology
June 2024